Clinical Trials Sponsored by Cyprus Broadcasting Corporation

Total 26 results

University of Cambridge
British Broadcasting Corporation

Completed

Trial of Different Dietary Fats on Blood Lipids and Metabolic Measures in Healthy Participants (COB)

Cardiovascular Risk Factor

United Kingdom
University of Glasgow
British Broadcasting Corporation

Completed

Impact of the Food Matrix on Iodine Bioavailability

Iodine Bioavailability

United Kingdom
University of Surrey
British Broadcasting Corporation

Completed

The Effectiveness of Commercial Weight Loss Programmes

Obesity

United Kingdom
Caerus Corporation

Enrolling by invitation

Study to Evaluate the OrthoCor Active System for Pain Relief

Pain

United States
Cerus Corporation

Recruiting

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS)

Anemia

United States, Puerto Rico
Cerus Corporation

Completed

A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components (PIPER)

Transfusion Related Acute Lung Injury

United States
Cerus Corporation

Completed

A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells (S303 RBC)

Focus: Assess Post Infusion Viability of S303 RBCs

United States
Cerus Corporation

Completed

Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia

Focus:Use of S303 RBCs in Patients With Acute Anemia

Germany
University of Cyprus
Cyprus University of Technology; University of Crete; Soroka University Medical... and other collaborators

Completed

Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches (MEDEA)

Atrial Fibrillation | Asthma in Children

Israel, Cyprus, Greece
Cerus Corporation

Active, not recruiting

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (ReCePI)

Anemia

United States
Cerus Corporation

Terminated

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

Acute Ebola Virus Disease

United States
Cerus Corporation

Completed

Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

Thalassemia Major

Turkey, Italy
Cerus Corporation

Terminated

A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

Healthy

United States
Cerus Corporation

Completed

Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days (TESSI)

Thrombocytopenia

United Kingdom
Cerus Corporation

Completed

In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days

Healthy

United States
Cerus Corporation

Completed

A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma

Healthy
Swiss Transfusion SRC
Cerus Corporation

Withdrawn

INTERCEPT Safety Evaluation on Whole Blood (POINT1africa)

Safety Issues
Newcastle University
University College, London; University of Leeds; British Broadcasting Corporation and other collaborators

Completed

Turmeric Anti-Inflammatory and Cell-Damage Trial (TACT)

Healthy Adults

United Kingdom
Swiss Transfusion SRC
Cerus Corporation

Withdrawn

INTERCEPT Safety Evaluation in Anemic Patients (POINT1africa)

Anemia
Cerus Corporation
American National Red Cross

Completed

A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components (TRUE)

Dengue Virus | Chikungunya Virus

Puerto Rico
Centro Nazionale Sangue
Terumo BCT; Cerus Corporation

Terminated

Italian Platelet Technology Assessment Study (IPTAS)

Lymphoma | Leukemia

Italy
Coalition for National Trauma Research
Cerus Corporation

Recruiting

Plasma Resuscitation Without Lung Injury (PROPOLIS)

Burns

United States
Weill Medical College of Cornell University
Cerus Corporation

Recruiting

Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding

Bleeding | Hypofibrinogenemia

United States
Emory University
National Heart, Lung, and Blood Institute (NHLBI); Cerus Corporation

Recruiting

Red Blood Cell Survival in Sickle Cell Disease

Sickle Cell Disease

United States
University of Cincinnati
Biomedical Advanced Research and Development Authority; Cerus Corporation

Unknown

Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units (BIO-CR-RBC)

Red Cell Survival in Healthy Volunteers

United States
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia

Clinical Trials Sponsored by Cyprus Broadcasting Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations